AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20538208 — intervention group
Group type: EXPERIMENTAL
Intervention: Wound infiltration of ropivacaine
Number of subjects: 102
Study 20538208 — intervention group
Group type: COMPARATOR
Intervention: Control group (no wound infiltration)
Number of subjects: 102
Study 20538208 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (ropivacaine and control)
Number of subjects: 102
Study 18772244 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone supplements
Number of subjects: 1276
Study 18772244 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol
Number of subjects: 1276
Study 18772244 — intervention group
Group type: COMPARATOR
Intervention: PCOS, acne, hirsutism
Number of subjects: 1276
Study 16438129 — intervention group
Group type: EXPERIMENTAL
Intervention: Artekin (dihydroartemisinin 40 mg and piperaquine 320 mg) given once a day for 3 days (Group B)
Number of subjects: 180
Study 16438129 — intervention group
Group type: COMPARATOR
Intervention: Artesunate 4 mg/kg/day and mefloquine 8 mg/kg/day orally once a day for 3 days (Group A)
Number of subjects: 180
Study 16438129 — intervention group
Group type: EXPERIMENTAL
Intervention: Artekin (dihydroartemisinin 40 mg and piperaquine 320 mg)
Number of subjects: 180
Study 16438129 — intervention group
Group type: COMPARATOR
Intervention: Artesunate 4 mg/kg/day and mefloquine 8 mg/kg/day
Number of subjects: 180
Study 12903625 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentaglobin (infused intravenously at 12 mL/h for 3 days)
Number of subjects: 11
Study 12903625 — intervention group
Group type: COMPARATOR
Intervention: Previous treatment period without Pentaglobin
Number of subjects: 11
Study 10573505 — intervention group
Group type: EXPERIMENTAL
Intervention: Active condition (physical activity)
Number of subjects: 10
Study 10573505 — intervention group
Group type: COMPARATOR
Intervention: Rest condition (no physical activity)
Number of subjects: 10
Study 7564347 — intervention group
Group type: EXPERIMENTAL
Intervention: UP 269-6 (180 mg)
Number of subjects: 16
Study 7564347 — intervention group
Group type: EXPERIMENTAL
Intervention: UP 269-6 (>= 40 mg)
Number of subjects: 16
Study 7564347 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 20 mg
Number of subjects: 16
Study 7564347 — intervention group
Group type: EXPERIMENTAL
Intervention: UP 269-6
Number of subjects: 16
Study 1939923 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure treatment
Number of subjects: 0
Study 1939923 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 339250 — intervention group
Group type: EXPERIMENTAL
Intervention: Transverse carpal ligament release alone
Number of subjects: 22
Study 339250 — intervention group
Group type: COMPARATOR
Intervention: Transverse carpal ligament release, external neurolysis of the median nerve, flexor synovectomy, and intraoperative corticosteroid instillation
Number of subjects: 22
Study 31770456 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole (P-glycoprotein inhibitor)
Number of subjects: 36
Study 31770456 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin (P-glycoprotein inducer)
Number of subjects: 36
Study 30908592 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive oxygen therapy (no supplemental oxygen if SpO2 ≥ 94%, n=21)
Number of subjects: 41
Study 30908592 — intervention group
Group type: COMPARATOR
Intervention: Liberal oxygen therapy (intubated patients: FiO2 1.0 in trauma bay, 0.8-1.0 elsewhere; spontaneously breathing patients: 15 L/min via non-rebreather mask, n=20)
Number of subjects: 41
Study 28394418 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon beta‐1a
Number of subjects: 0
Study 28394418 — intervention group
Group type: EXPERIMENTAL
Intervention: Every‐2‐week dosing regimen of Peginterferon beta‐1a
Number of subjects: 0
Study 28394418 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26081864 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehab-let (touchscreen tablet self-training protocol)
Number of subjects: 40
Study 26081864 — intervention group
Group type: COMPARATOR
Intervention: Traditional self-training program using therapeutic aids (balls, blocks, pegs)
Number of subjects: 40
Study 23569345 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/kg IL‐1Ra via ear vein 18 h, 2 d and 4 d after D‐gal induction (Group B)
Number of subjects: 28
Study 23569345 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/kg IL‐1Ra via ear vein 18 h after D‐gal induction, MSCs transplantation at 24 h after D‐gal induction, and 2 mg/kg IL‐1Ra via ear vein 1 d and 3 d after surgery (Group D)
Number of subjects: 28
Study 23569345 — intervention group
Group type: COMPARATOR
Intervention: 40 mL saline via portal vein 24 h after D‐gal induction (Group A)
Number of subjects: 28
Study 23569345 — intervention group
Group type: COMPARATOR
Intervention: Approximately 1 × 10(8) GFP‐MSCs suspended in 40 mL normal saline via portal vein 24 h after D‐gal induction (Group C)
Number of subjects: 28
Study 22143217 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral care education for caregivers (6 weeks duration)
Number of subjects: 54
Study 22143217 — intervention group
Group type: COMPARATOR
Intervention: Usual oral care from control group caregivers
Number of subjects: 54
Study 19153867 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized-vibration group
Number of subjects: 33
Study 19153867 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-vibration group
Number of subjects: 33
Study 19153867 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 33
Study 17892982 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol therapy
Number of subjects: 0
Study 17892982 — intervention group
Group type: COMPARATOR
Intervention: Losartan therapy
Number of subjects: 0
Study 15177489 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 252
Study 15177489 — intervention group
Group type: COMPARATOR
Intervention: Itraconazole
Number of subjects: 252
Study 11474773 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg omeprazole
Number of subjects: 18
Study 11474773 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg lansoprazole
Number of subjects: 18
Study 11474773 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg sodium rabeprazole
Number of subjects: 18
Study 9604880 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinamide (slow release, 1.2 g x m(‐2) x day(‐1))
Number of subjects: 55
Study 9604880 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 7924780 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired awareness of hypoglycemia
Number of subjects: 60
Study 7924780 — intervention group
Group type: COMPARATOR
Intervention: Normal awareness of hypoglycemia
Number of subjects: 60
Study 3260759 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole
Number of subjects: 70
Study 3260759 — intervention group
Group type: COMPARATOR
Intervention: Pentamidine
Number of subjects: 70
Study 31736283 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Conversation Skills (HCS) intervention
Number of subjects: 0
Study 29880010 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 0
Study 29880010 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 0
Study 29880010 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28398946 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 46
Study 28398946 — intervention group
Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 46
Study 28398946 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-Duration HIIT
Number of subjects: 46
Study 28398946 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (all groups combined)
Number of subjects: 46
Study 28398946 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (HIIT, MICT, Short-Duration HIIT)
Number of subjects: 46
Study 26817206 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin D supplement (2,000 IUs/day)
Number of subjects: 24
Study 26817206 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 23284036 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocolized patient‐tailored treatment (PPT) of symptoms
Number of subjects: 152
Study 21640089 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme replacement therapy (ERT)
Number of subjects: 40
Study 21640089 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline median values of biomarkers
Number of subjects: 40
Study 21640089 — intervention group
Group type: COMPARATOR
Intervention: Comparison between mild and moderate GP subgroups
Number of subjects: 40
Study 19084937 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week pegylated interferon alpha-2a (peg-IFN-alpha 2a) monotherapy, 180 microg or 90 microg once weekly
Number of subjects: 33
Study 19084937 — intervention group
Group type: COMPARATOR
Intervention: 12-week pegylated interferon alpha-2a (peg-IFN-alpha 2a) monotherapy, 180 microg or 90 microg once weekly
Number of subjects: 33
Study 18039239 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive group physical therapy (PT)
Number of subjects: 96
Study 18039239 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 96
Study 14979498 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium (18 microg once daily)
Number of subjects: 519
Study 14979498 — intervention group
Group type: COMPARATOR
Intervention: Ipratropium (2 puffs of 20 microg administered four times daily)
Number of subjects: 519
Study 14979498 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium
Number of subjects: 519
Study 14979498 — intervention group
Group type: COMPARATOR
Intervention: Ipratropium
Number of subjects: 519
Study 11568834 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative compression
Number of subjects: 130
Study 9652994 — intervention group
Group type: EXPERIMENTAL
Intervention: MFP plus calcium (20 mg of equivalent fluoride + 1000 mg calcium)
Number of subjects: 200
Study 9652994 — intervention group
Group type: COMPARATOR
Intervention: Calcium only
Number of subjects: 200
Study 9652994 — intervention group
Group type: EXPERIMENTAL
Intervention: MFP plus calcium
Number of subjects: 200
Study 10150434 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrosurgical loop conization
Number of subjects: 30
Study 10150434 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser conization
Number of subjects: 30
Study 10150434 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold knife conization
Number of subjects: 30
Study 10150434 — intervention group
Group type: COMPARATOR
Intervention: All methods (cold knife, laser, electrosurgical loop)
Number of subjects: 30
Study 3135831 — intervention group
Group type: EXPERIMENTAL
Intervention: 17 alpha-hydroxyprogesterone caproate
Number of subjects: 64
Study 3135831 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 31857217 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone (20-80 mg/day)
Number of subjects: 343
Study 31857217 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 343
Study 30599772 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive computer play training (4 times per week, 20 minutes per session for 6 weeks)
Number of subjects: 18
Study 30599772 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual physiotherapy programme)
Number of subjects: 18
Study 30599772 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive computer play training
Number of subjects: 18
Study 28402092 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided epidural placement
Number of subjects: 0
Study 28402092 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham (non-ultrasound) epidural placement
Number of subjects: 0
Study 28402092 — intervention group
Group type: COMPARATOR
Intervention: Control group (no epidural)
Number of subjects: 0
Study 25572878 — intervention group
Group type: EXPERIMENTAL
Intervention: Charité Cesarean Birth (CCB)
Number of subjects: 0
Study 25572878 — intervention group
Group type: COMPARATOR
Intervention: Classical cesarean section (Control)
Number of subjects: 0
Study 24928083 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX4 plus cetuximab
Number of subjects: 2559
Study 24928083 — intervention group
Group type: COMPARATOR
Intervention: FOLFOX4 alone
Number of subjects: 2559
Study 22980891 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐FVOO (250 mg total phenols/kg)
Number of subjects: 12
Study 22980891 — intervention group
Group type: EXPERIMENTAL
Intervention: M‐FVOO (500 mg total phenols/kg)
Number of subjects: 12
Study 22980891 — intervention group
Group type: EXPERIMENTAL
Intervention: H‐FVOO (750 mg total phenols/kg)
Number of subjects: 12
Study 19939281 — intervention group
Group type: EXPERIMENTAL
Intervention: Laterally wedged insoles (5 degrees)
Number of subjects: 20
Study 17244785 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 45 mg daily (PIO)
Number of subjects: 31
Study 17244785 — intervention group
Group type: COMPARATOR
Intervention: Placebo (CON)
Number of subjects: 31
Study 16286549 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild Cognitive Impairment (MCI) diagnosis based on comprehensive neuropsychological, functional, and neurologic assessments.
Number of subjects: 1315
Study 16286549 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and education as factors in MCI diagnosis.
Number of subjects: 1315
Study 16286549 — intervention group
Group type: EXPERIMENTAL
Intervention: APOE E4 allele association with MCI.
Number of subjects: 1315
Study 11965508 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (60 mg RE to mothers and 7.5 mg RE to infants with each OPV dose)
Number of subjects: 0
Study 11965508 — intervention group
Group type: COMPARATOR
Intervention: Placebo (given to mothers and infants at each OPV contact)
Number of subjects: 0
Study 9825815 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased doses of tacrolimus (median increase of 1.89-fold, range: 1.2-5 mg)
Number of subjects: 10
Study 8008540 — intervention group
Group type: EXPERIMENTAL
Intervention: Goat's milk
Number of subjects: 30
Study 8008540 — intervention group
Group type: COMPARATOR
Intervention: Cow's milk
Number of subjects: 30
Study 2466045 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (50 micrograms, sc)
Number of subjects: 20
Study 2466045 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (50 micrograms, twice daily, sc)
Number of subjects: 20
Study 2466045 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (50 micrograms, sc) given 45 min before flush stimulation
Number of subjects: 20
Study 2466045 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered in the same way
Number of subjects: 20
Study 30810750 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor-based problem solving intervention
Number of subjects: 20
Study 30810750 — intervention group
Group type: COMPARATOR
Intervention: Optimal movement patterns intervention
Number of subjects: 20
Study 30810750 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 20
Study 27936452 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 0
Study 25995333 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagitocin 400 IU
Number of subjects: 64
Study 25995333 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagitocin 100 IU
Number of subjects: 64
Study 25995333 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 24196330 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG 1440 nm laser treatment
Number of subjects: 15
Study 20971520 — intervention group
Group type: EXPERIMENTAL
Intervention: AF+C
Number of subjects: 189
Study 20971520 — intervention group
Group type: COMPARATOR
Intervention: CF
Number of subjects: 189
Study 18203019 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab 375 mg/m2 once weekly for 4 weeks
Number of subjects: 123
Study 18203019 — intervention group
Group type: COMPARATOR
Intervention: Rituximab alone (n = 36)
Number of subjects: 123
Study 18203019 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab in combination with interferon alpha-2a (IFN) (n = 33)
Number of subjects: 123
Study 18203019 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal residual disease (MRD) evaluation in patients who achieved CR
Number of subjects: 123
Study 16402269 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendamustine and prednisone (BP)
Number of subjects: 131
Study 16402269 — intervention group
Group type: COMPARATOR
Intervention: Melphalan and prednisone (MP)
Number of subjects: 131
Study 14609612 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone with percutaneous balloon mitral commissurotomy
Number of subjects: 38
Study 14609612 — intervention group
Group type: COMPARATOR
Intervention: No amiodarone
Number of subjects: 38
Study 10910828 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-dose aprotinin regimen
Number of subjects: 0
Study 10910828 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose aprotinin regimen
Number of subjects: 0
Study 8760643 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg of lorazepam, orally, one hour before induction of anaesthesia
Number of subjects: 26
Study 8760643 — intervention group
Group type: COMPARATOR
Intervention: Placebo, orally, one hour before induction of anaesthesia
Number of subjects: 26
Study 1425205 — intervention group
Group type: EXPERIMENTAL
Intervention: Seaprose (60 mg/8 h) plus erythromycin (500 mg/8 h)
Number of subjects: 40
Study 1425205 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin (500 mg/8 h) plus placebo
Number of subjects: 40
Study 3967167 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dacarbazine plus intradermal injection of the methanol‐extracted residue of bacillus Calmette‐Guerin (BCG)
Number of subjects: 70
Study 3967167 — intervention group
Group type: COMPARATOR
Intervention: Intravenous dacarbazine alone
Number of subjects: 70
Study 29276857 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroop Color and Word test to induce mental fatigue
Number of subjects: 16
Study 29276857 — intervention group
Group type: COMPARATOR
Intervention: Watching an emotionally neutral video
Number of subjects: 16
Study 27251474 — intervention group
Group type: EXPERIMENTAL
Intervention: Three additional imbricating figure‐of‐X sutures (Arm 2)
Number of subjects: 263
Study 27251474 — intervention group
Group type: COMPARATOR
Intervention: Single‐layer continuous closure (Arm 1)
Number of subjects: 263
Study 24662230 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional repeated sprint training (RS)
Number of subjects: 13
Study 24662230 — intervention group
Group type: COMPARATOR
Intervention: Normal training
Number of subjects: 13
Study 20977661 — intervention group
Group type: EXPERIMENTAL
Intervention: Household salt iodine content
Number of subjects: 2488
Study 20977661 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct iodine supplementation during pregnancy
Number of subjects: 2488
Study 21190639 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication switches
Number of subjects: 908
Study 21190639 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuations
Number of subjects: 908
Study 21190639 — intervention group
Group type: EXPERIMENTAL
Intervention: Other access problems
Number of subjects: 908
Study 21190639 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple access problems
Number of subjects: 908
Study 21190639 — intervention group
Group type: COMPARATOR
Intervention: No access problems
Number of subjects: 908
Study 19007605 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal contraception
Number of subjects: 0
Study 19007605 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency contraception
Number of subjects: 0
Study 15673878 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-dose IV ketamine (0.5 mg/kg bolus followed by 3 mcg/kg/min during surgery and 1.5 mcg/kg/min for 48 hours)
Number of subjects: 0
Study 15673878 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-dose IV ketamine
Number of subjects: 0
Study 15673878 — intervention group
Group type: COMPARATOR
Intervention: Control group (saline)
Number of subjects: 0
Study 15673878 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 14600187 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam mesylate (0.05 microg/kg/min titrated to 0.10 microg/kg/min)
Number of subjects: 315
Study 14600187 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 315
Study 14600187 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam mesylate
Number of subjects: 315
Study 10992661 — intervention group
Group type: EXPERIMENTAL
Intervention: Framing the health plan decision using a risk message
Number of subjects: 0
Study 10992661 — intervention group
Group type: COMPARATOR
Intervention: Standard framing of health plan choice
Number of subjects: 0
Study 8866316 — intervention group
Group type: EXPERIMENTAL
Intervention: Demineralized freeze‐dried bone allograft reconstituted with 50 mg/ml tetracycline (DFDBA + TCN)
Number of subjects: 15
Study 8866316 — intervention group
Group type: EXPERIMENTAL
Intervention: Demineralized freeze‐dried bone allograft alone (DFDBA)
Number of subjects: 15
Study 8866316 — intervention group
Group type: COMPARATOR
Intervention: Debridement only (D)
Number of subjects: 15
Study 1333782 — intervention group
Group type: EXPERIMENTAL
Intervention: Single, high dose of aspirin
Number of subjects: 0
Study 1333782 — intervention group
Group type: COMPARATOR
Intervention: Low chloride cough challenge
Number of subjects: 0
Study 6474351 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg and dipyridamole 75 mg
Number of subjects: 100
Study 6474351 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 30351167 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 0
Study 30351167 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 0
Study 30063860 — intervention group
Group type: EXPERIMENTAL
Intervention: Ta-1 plus ETV
Number of subjects: 690
Study 30063860 — intervention group
Group type: COMPARATOR
Intervention: ETV monotherapy
Number of subjects: 690
Study 26850868 — intervention group
Group type: EXPERIMENTAL
Intervention: Sialendoscopy
Number of subjects: 20
Study 24587006 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous palonosetron
Number of subjects: 25